Randomized Phase 2 study demonstrates improved survival outcomes in previously treated metastatic colorectal cancer, indicating potential for better third-line therapy options.
EZFB significantly improved survival outcomes compared with regorafenib in patients with mCRC as a third-line treatment, with a manageable safety profile. Further investigation is warranted, given the clinically meaningful improvements in progression-free survival and overall survival.
No takes yet. Share an insight, caveat, or question.
Cecchini et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: